NCT03727724 (AFACET) is a Phase 2 clinical trial of Afatinib in Carcinoma, Non-Small-Cell Lung, sponsored by The Netherlands Cancer Institute.

Who is sponsoring NCT03727724?

NCT03727724 is sponsored by The Netherlands Cancer Institute.

What drugs are being tested in NCT03727724?

Interventions in NCT03727724: Afatinib, Cetuximab.

What condition does NCT03727724 study?

NCT03727724 studies Carcinoma, Non-Small-Cell Lung.

Is NCT03727724 still recruiting?

NCT03727724 is currently completed. Last updated 18 October 2023.

Last reviewed 2023-10-18 · How we verify

NCT03727724: AFACET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

Completed Phase 2 Last updated 18 October 2023

What this trial tests

Phase 2 trial testing Afatinib in Carcinoma, Non-Small-Cell Lung in 37 participants. Completed in 6 September 2022.

Timeline

4 December 2018

Primary endpoint
6 September 2022

6 September 2022

Quick facts

Lead sponsor	The Netherlands Cancer Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	4 December 2018
Primary completion	6 September 2022
Estimated completion	6 September 2022
Sites	4 locations across Netherlands

Drugs / interventions tested

Afatinib (afatinib) — full drug profile →
Cetuximab (cetuximab) — full drug profile →

Conditions studied

Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →

Sponsor

The Netherlands Cancer Institute

Who can join

18 and older, any sex, with Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm open-label multi-center phase II study, investigating disease control rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.
Vyse S, Huang PH. · · 2019 · cited 262× · PMID 30854234 · DOI 10.1038/s41392-019-0038-9
Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.
Meador CB, Sequist LV, Piotrowska Z. · · 2021 · cited 77× · PMID 34301786 · DOI 10.1158/2159-8290.cd-21-0226
Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.
Qin Y, Jian H, Tong X, Wu X, et al · · 2020 · cited 47× · PMID 32412152 · DOI 10.1002/1878-0261.12710
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives.
Hou J, Li H, Ma S, He Z, et al · · 2022 · cited 44× · PMID 35418149 · DOI 10.1186/s40364-022-00372-6
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.
Baysal H, De Pauw I, Zaryouh H, Peeters M, et al · · 2021 · cited 41× · PMID 34557197 · DOI 10.3389/fimmu.2021.737311
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.
Chai X, Yinwang E, Wang Z, Wang Z, et al · · 2021 · cited 36× · PMID 34722241 · DOI 10.3389/fonc.2021.692788
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
Brazel D, Kroening G, Nagasaka M. · · 2022 · cited 22× · PMID 36255589 · DOI 10.1007/s40259-022-00556-4
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.
Vyse S, Huang PH. · · 2022 · cited 22× · PMID 34913823 · DOI 10.1080/14737140.2022.2016397

Verify or expand the search:

Other trials of Afatinib

Trials testing the same drug.

NCT07040956 — A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neo · Phase 2 · recruiting
NCT07010120 — A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head · Phase 1, PHASE2 · recruiting
NCT06804850 — Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable H · Phase 2 · withdrawn
NCT06741982 — A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy an · Phase 1 · recruiting
NCT06494189 — Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable · Phase 1 · completed

Other recruiting trials for Carcinoma, Non-Small-Cell Lung

Currently open trials in the same condition.

NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting

Other The Netherlands Cancer Institute trials

Trials by the same sponsor.

NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03727724 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
Last refreshed: 18 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03727724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing